We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Vivani Medical will spin off Cortigent, its neurostimulation business, as an independently publicly traded company as it looks to prioritise its portfolio of weight loss drug implants. While Vivani ...

The American Society of Pain and Neuroscience (ASPN) has just issued UPDATED guidelines for physicians using neuromodulation ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. If we consider the ...

A team of experts from the Icahn School of Medicine at Mount Sinai has become the first in the United States to perform a ...

Abbott received a breakthrough device designation from the US Food and Drug Administration (FDA) to investigate the use of ...

We anticipate Livanova can bring leverage down to the target range by 2027, which would put the firm's debt at levels typical of medtech firms. Interest coverage remains well within covenants, though, ...

Case marks the beginning of a multi-site pivotal trial to evaluate Abbott’s system for management of treatment-resistant ...

Analysts have recently evaluated Abbott Laboratories and provided 12-month price targets. The average target is $145.12, ...

A new study, led by experts at the University of Nottingham, has found that patients who need treatment for neurological and mental health disorders, would favour non-invasive neuromodulation ...

Neuspera Medical today announced six-month pivotal clinical trial data highlighting the efficacy of its battery-free percutaneous sacral neuromodulation (pSNM) system. Findings showed comparable ...